All news

Ionis halves Tryngolza 2026 sales guidance to about $50 million, shares sink 19% premarket

StockTitan (Ionis release) · · AI-summarised by FinFlash

Ionis Pharmaceuticals cut its 2026 Tryngolza sales guidance to about $50 million from

So What?

The Tryngolza miss raises doubts about Ionis's commercial launch execution and pressures IONS and peers in rare-disease biotech; watch whether full-year revenue guidance holds.

Read original source

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.